AI assistant
ACADIA PHARMACEUTICALS INC — Director's Dealing 2013
Sep 5, 2013
31237_dirs_2013-09-05_d19ae912-d7fe-4968-b3f6-3ef444cee5a6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2013-09-03
Reporting Person: Rasmussen Torsten (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-09-03 | Common Stock | M | 10000 | $2.16 | Acquired | 18500 | Indirect |
| 2013-09-03 | Common Stock | M | 10000 | $1.30 | Acquired | 28500 | Indirect |
| 2013-09-03 | Common Stock | M | 20000 | $1.30 | Acquired | 48500 | Indirect |
| 2013-09-03 | Common Stock | S | 40000 | $20.2775 | Disposed | 8500 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-09-03 | Stock option (right to buy) | $2.16 | M | 10000 | Disposed | 2019-06-11 | Common stock (10000) | Indirect |
| 2013-09-03 | Stock option (right to buy) | $1.30 | M | 10000 | Disposed | 2020-06-10 | Common stock (10000) | Indirect |
| 2013-09-03 | Stock option (right to buy) | $1.30 | M | 20000 | Disposed | 2020-06-10 | Common stock (20000) | Indirect |
Footnotes
F1: Shares and options are held by Morgan Management ApS, a Danish corporation in which Mr. Rasmussen has a controlling interest.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.14 to $20.42 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
F4: 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 12, 2009.
F5: 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 11, 2010.